A Defining Moment for Tobacco Harm Reduction: FEELM Shares the Stage With Industry Giants to Reducing Smoking Rates and Save Lives
FEELM, the flagship atomization technology brand belonging to SMOORE – a global leader in atomisation technology solutions – today joined global health advocates, leading scientists, politicians, and industry experts at a virtual conference on tobacco harm reduction.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230427005527/en/
(Photo: Business Wire)
IN FOCUS, an annual half-day event organised by the Global Tobacco and Nicotine Forum (GTNF) which aims to consider key issues affecting the sector, this year returned to the theme of addressing tobacco harm reduction, and how best to support smokers to transition to reduced-risk products, including vapes, heat-not-burn products, and oral nicotine.
Ahead of the virtual conference, FEELM representatives spoke at a breakfast event in central London alongside Andrew Lewer MBE MP, the Vice Chair of the UK Parliament’s All-Party Parliamentary Group for Vaping, as well as Delon Human, the President of Health Diplomats and a former Secretary-General of the World Medical Association.
The UK Government has consistently set out that its harm reduction strategy centres around the use of vaping as a tool for smoking cessation, and in encouraging existing smokers to transition to a less harmful alternative. Since 2015, Public Health England (now the Office for Health Improvement and Disparities) has been clear that vaping is at least 95 per cent less harmful than smoking, after a review of all available independent and peer-reviewed research. This was supported by a further review of the evidence in 2018, and by Dr Javed Khan in his independent report last year into “making smoking obsolete”, as well as in the recent speech earlier this month by the Minister for Public Health, Neil O’Brien MP.
However, concerns have been raised about the growth in the availability of illegal and non-compliant vapes, as well as the increased rates of youth access to nicotine products. As a global leader of atomisation technology solutions, FEELM is focused on ensuring compliance with all regulations in the markets where it operates, and supporting its industry clients through research investment and technological innovation.
Echo Liu, FEELM’s European Division Director, said:
"We welcome the UK Government's ongoing recognition of the potential that vaping has to achieve its ambitions for a smoke-free future, and we are committed to working with regulators and the wider industry to address the key challenges the sector faces."
"Our vaping solutions have been widely adopted in more than fifty markets – including the UK, France, and Germany – and these are helping millions of smokers to improve their health by switching to vaping."
FEELM’s disposable ceramic coil technologies have already been launched in markets like France, UK, Belgium, on behalf of their clients, and will soon be available in other key markets. The FEELM MAX solution, which offers more puffs, greater taste consistency, and a fully visible e-liquid measure, is the best disposable available which ensures regulatory compliance.
FEELM will be launching its FEELM MAX at the Birmingham Vaper Expo on 13 May.
As a flagship OEM technology brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Through its ceramic coil heating technology, used in around one in every two closed pods sold globally, FEELM provides its vaping solutions to b2c companies in fifty countries worldwide, including RELX, HEXA, KIWI, and NJOY, among others.
SMOORE is the global leader in offering vaping technology solutions, including manufacturing OEM vaping devices and vaping components for heat-not-burn products, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio, and a diverse customer base.
The Global Tobacco & Nicotine Forum (GTNF) is the world’s leading annual forum discussing the future of the tobacco and nicotine industries. From its launch in Rio de Janeiro in 2008 to the present day, the GTNF has become the global exchange for views and ideas between public health experts, government representatives, the industry, and investors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005527/en/
For more information or journalist queries, please contact Tommy Gilchrist on 0044 7388 110 679 or via email@example.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Inca Arrives to USA, a Strong Outlook for Peru Tourism Recovery27.5.2023 18:00:00 EEST | Press release
The Inca emperor walks the streets of New York City while his retinue dances tirelessly along the way, garnering the attention of the passers-by who stopped to stare and take video of the captivating scene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230526005330/en/ Peruvian actors from Cusco promoting the Inti Raymi 2023 in New York City, as tourism in Peru is once more on the rise. (Photo: PROMPERÚ). This performance was displayed by 30 actors from Cusco, Peru, as a promotional strategy to get Peru back in the news and in front of potential visitors in a positive way. The upcoming Inti Raymi (Festival of the Sun), a thousand-year-old ritual worshiping the Sun God and asking him to make the days longer, was promoted in the Big Apple in order to put the most notable celebration of Cusco’s calendar in the international spotlight. Inti Raymi honors the Sun each June 24th and celebrates the winter solstice of the Southern H
10th Annual World Patient Safety, Science & Technology Summit Is Sold Out!27.5.2023 07:10:00 EEST | Press release
Registration for the 10th Annual Patient Safety, Science & Technology Summit is now closed. This in-person Summit marks the nonprofit’s 10th anniversary and will be held in Newport Beach, California, from June 1 to 2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230526005374/en/ Annual World Patient Safety, Science & Technology Summit (Photo: Business Wire) “We are very encouraged at the response we received for our first in-person Summit since Covid-19,” said Dr. Michael Ramsay, CEO, Patient Safety Movement Foundation. “Many organizations felt a significant setback caused by the Covid-19 pandemic, but I believe this Summit will be the perfect way to get back on course. We have an incredible program designed for our 10th anniversary, with renowned speakers from around the world, including President Bill Clinton, Dr. Don Berwick, Dr. Neelam Dhingra, Sir Liam Donaldson, Dr. Peter Pronovost, Dr. Jannicke Mellin-Olsen, Dr. Mic
Sims Limited Achieves Climate Leaders Asia-Pacific 2023 Recognition27.5.2023 05:49:00 EEST | Press release
Sims Limited (ASX: SGM), a global leader in sustainability and an enabler of the circular economy, has been named to the Financial Times 2023 Asia-Pacific Climate Leaders list for the second time. Sims Limited was one of 275 companies on the prestigious list, which highlights companies that have made genuine greenhouse gas emissions reductions relative to their revenues over a five-year period. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230526005346/en/ FT-Statista Climate Leaders 2023 logo (Graphic: Business Wire) For the second consecutive year, Financial Times and Statista examined publicly available disclosures of more than 2,000 companies in the Asia-Pacific region to compile the Climate Leaders Asia-Pacific list. The list is comprised of companies that achieved the greatest reduction in their core emissions intensity between 2016 and 2021 – that is, their Scope 1 and 2 greenhouse gas emissions in relation to revenu
Skyflow Radically Simplifies Data Residency26.5.2023 18:00:00 EEST | Press release
Today Skyflow, the data privacy vault company, announced new data residency capabilities including Asia-Pacific instances in Japan, Indonesia, India, and Bahrain, and an expansion of its footprint in EMEA and North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230526005072/en/ (Graphic: Business Wire) With Skyflow, companies that store sensitive customer data can meet regulatory requirements for localized storage, provable and auditable data protection, and governance – simply by leveraging Skyflow’s global vault infrastructure. This enables global expansion to reach new customers in new markets, while minimizing complexity and cost. For example, SaaS ISVs can scale and sell their product in both EMEA and APAC without adding instances. Replicating Instances is Expensive and Slow Today, companies that want to expand internationally face a technically complex and expensive proposition: replicate all of your cloud inf
FORE Biotherapeutics to Present Promising New Data from Phase 1/2a Trial Evaluating Plixorafenib (FORE8394) in Patients With BRAF-Altered Advanced Solid and Central Nervous System Tumors at ASCO 202326.5.2023 16:00:00 EEST | Press release
FORE Biotherapeutics today announced new clinical data from the Phase 1/2a clinical trial for plixorafenib (FORE8394), a novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations. The results demonstrate promising single-agent activity against BRAF-altered tumors, including primary central nervous system (CNS) tumors, and will be featured in presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6, 2023, in Chicago, IL. “The updated data from our Phase 1/2a study further reinforces plixorafenib’s differentiated clinical profile,” said Stacie Shepherd, MD, PhD, and Chief Medical Officer of FORE. “Plixorafenib has demonstrated both promising antitumor activity with durable responses and favorable tolerability as a single agent in patients with advanced BRAF-altered tumors. Notably, plixorafenib has a striking safety profile as compared to the currently approved BRAF/MEK and investiga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom